Co-Authors
This is a "connection" page, showing publications co-authored by Susannah Spiess and Mary Eileen Dolan.
Connection Strength
4.147
-
Population differences in the rate of proliferation of international HapMap cell lines. Am J Hum Genet. 2010 Dec 10; 87(6):829-33.
Score: 0.388
-
Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science. Pharmacogenomics. 2013 Sep; 14(12):1383-7.
Score: 0.235
-
Clinical translation of cell-based pharmacogenomic discovery. Clin Pharmacol Ther. 2012 Oct; 92(4):425-7.
Score: 0.219
-
Population differences in microRNA expression and biological implications. RNA Biol. 2011 Jul-Aug; 8(4):692-701.
Score: 0.202
-
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res. 2011 Aug 15; 17(16):5490-500.
Score: 0.202
-
The use of genomic information to optimize cancer chemotherapy. Semin Oncol. 2011 Apr; 38(2):186-95.
Score: 0.199
-
Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A. 2010 May 18; 107(20):9287-92.
Score: 0.186
-
Expression and alternative splicing of folate pathway genes in HapMap lymphoblastoid cell lines. Pharmacogenomics. 2009 Apr; 10(4):549-63.
Score: 0.173
-
FstSNP-HapMap3: a database of SNPs with high population differentiation for HapMap3. Bioinformation. 2008; 3(3):139-41.
Score: 0.168
-
Population-specific GSTM1 copy number variation. Hum Mol Genet. 2009 Jan 15; 18(2):366-72.
Score: 0.168
-
SNPinProbe_1.0: a database for filtering out probes in the Affymetrix GeneChip human exon 1.0 ST array potentially affected by SNPs. Bioinformation. 2008 Aug 01; 2(10):469-70.
Score: 0.165
-
Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans. Pharmacogenet Genomics. 2008 Jun; 18(6):545-9.
Score: 0.163
-
Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clin Pharmacol Ther. 2014 Jun; 95(6):644-52.
Score: 0.121
-
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood. 2013 May 23; 121(21):4366-76.
Score: 0.114
-
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2013 Jan 15; 19(2):491-9.
Score: 0.111
-
Mixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancer. PLoS Genet. 2012 Feb; 8(2):e1002525.
Score: 0.105
-
Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer. 2012 Aug 15; 118(16):4063-73.
Score: 0.105
-
Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2013 Feb; 13(1):35-43.
Score: 0.102
-
Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One. 2011; 6(7):e21920.
Score: 0.101
-
Genetic architecture of transcript-level variation in humans. Am J Hum Genet. 2008 May; 82(5):1101-13.
Score: 0.081
-
Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet. 2008 Mar; 82(3):631-40.
Score: 0.080
-
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A. 2007 Jun 05; 104(23):9758-63.
Score: 0.076
-
Poly-omic prediction of complex traits: OmicKriging. Genet Epidemiol. 2014 Jul; 38(5):402-15.
Score: 0.061
-
Integrative genomics: quantifying significance of phenotype-genotype relationships from multiple sources of high-throughput data. Front Genet. 2012; 3:202.
Score: 0.058
-
Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival. J Natl Cancer Inst. 2013 Feb 20; 105(4):302-9.
Score: 0.056
-
Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2013 Jan; 14(1):23-34.
Score: 0.056
-
Variants affecting exon skipping contribute to complex traits. PLoS Genet. 2012; 8(10):e1002998.
Score: 0.055
-
Copy number polymorphisms and anticancer pharmacogenomics. Genome Biol. 2011; 12(5):R46.
Score: 0.050
-
Exprtarget: an integrative approach to predicting human microRNA targets. PLoS One. 2010 Oct 21; 5(10):e13534.
Score: 0.048
-
PACdb: a database for cell-based pharmacogenomics. Pharmacogenet Genomics. 2010 Apr; 20(4):269-73.
Score: 0.046
-
Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet. 2010 Apr 01; 6(4):e1000888.
Score: 0.046
-
Comprehensive survey of SNPs in the Affymetrix exon array using the 1000 Genomes dataset. PLoS One. 2010 Feb 23; 5(2):e9366.
Score: 0.046
-
SCAN: SNP and copy number annotation. Bioinformatics. 2010 Jan 15; 26(2):259-62.
Score: 0.045
-
A pharmacogene database enhanced by the 1000 Genomes Project. Pharmacogenet Genomics. 2009 Oct; 19(10):829-32.
Score: 0.045
-
Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res. 2011 May; 157(5):265-72.
Score: 0.025
-
Comprehensive evaluation of the contribution of X chromosome genes to platinum sensitivity. Mol Cancer Ther. 2011 Mar; 10(3):472-80.
Score: 0.024
-
Identification of common genetic variants that account for transcript isoform variation between human populations. Hum Genet. 2009 Feb; 125(1):81-93.
Score: 0.021